Antitargets and Drug Safety

Name: Antitargets and Drug Safety
Brand: Wiley-VCH
Price: 151.99 EUR
Availability: OnlineOnly

Laszlo Urban Vinod F. Patel Roy Vaz(Herausgeber*in)

Wiley-VCH (Verlag)

1. Auflage

Erschienen am 23. Februar 2015

528 Seiten

E-Book

ePUB mit Adobe-DRM

Systemvoraussetzungen

978-3-527-67366-7 (ISBN)

151,99 €inkl. 7% MwSt.

Systemvoraussetzungen

für ePUB mit Adobe-DRM

E-Book Einzellizenz

Als Download verfügbar

Beschreibung

Weitere Details

Weitere Ausgaben

Personen

Laszlo Urban received his MD and PhD in neurophysiology/neuropharmacology in Hungary, and was visiting professor at Duke University between 1987 and 1989. He is currently global head of Preclinical Safety Profiling at the Novartis Institutes for Biomedical Research, Cambridge, USA, and was previously the Deputy Head of the Novartis Institute for Medical Sciences in London, UK. Dr. Urban has over 130 scientific articles, book chapters and patents to his name.

Roy J. Vaz received his PhD in organic chemistry from the University of Florida, Gainesville, an MBA from the University of Illinois, and most recently an MS in molecular biology from Lehigh University, USA. He is currently a senior distinguished scientist at Sanofi Pharmaceuticals in Waltham, MA, and was previously Director of the Investigative Product Optimization department under Aventis. He has worked at Bristol-Myers Squibb as Principal Scientist as well as at Tripos, Inc, as a research scientist. Dr. Vaz has authored or co-authored around 45 publications in peer-reviewed journals, eight book chapters and several patents.

Vinod Patel gained his BSc in applied chemistry from Leicester Polytechnic, and a PhD in synthetic organic chemistry from Nottingham University, UK. He took up a post-doctoral fellowship at the University of Rochester, NY, USA, before joining Eli Lilly & Company, where he spent the next nine years as a medicinal chemist in the oncology division. He then joined Kinetix Pharmaceuticals, which was acquired by Amgen and Dr. Patel joined their new Cambridge facility as head of medicinal chemistry. In 2011, he joined Sanofi oncology research as head of medicinal chemistry where he is currently head of chemical research in lead generation candidate realization. Dr. Patel has over 50 publications and some 50 patents to his name.

Herausgeber*in

Laszlo Urban

Swiss Institute of Technology (ETH), Zürich, Switzerland

Vinod F. Patel

Swiss Institute of Technology (ETH), Zürich, Switzerland

Roy Vaz

Swiss Institute of Technology (ETH), Zürich, Switzerland

Reihen-Herausgeber

Raimund Mannhold

Swiss Institute of Technology (ETH), Zürich, Switzerland

Hugo Kubinyi

Swiss Institute of Technology (ETH), Zürich, Switzerland

Gerd Folkers

Swiss Institute of Technology (ETH), Zürich, Switzerland

Inhalt

#01 Analysis of marketed drugs: The utility of AERS for early drug discovery/pitfalls
#02 In silico prediction of drug side effects
#03 Translational value of preclinical safety assessment: System organ class (SOC) representation of off-targets
#04 Pathological conditions associated with the disturbance of 5HT receptors
#05 Drug-induced Liver Injury ? Clinical and Diagnostic Aspects
#06 Mechanistic Safety Biomarkers for Drug-Induced Liver Injury
#07 In vitro models for the Prediction of Drug-Induced Liver Injury in Lead Discovery
#08 Transporters in the liver
#09 Mechanistic Modeling of Drug-Induced Liver Injury (DILI)
#10 Functional Cardiac Safety Evaluation of Novel Therapeutics
#11 Cav1.2
#12 Cardiac Sodium Current (Nav1.5)
#13 Circulating biomarkers for cardiotoxicity: reverse translation from human to preclinical species
#14 The Mechanistic Basis of hERG Blockade and the Proarrhythmic Effects Thereof
#15 Introduction to Kinase Anti-Targets
#16 Clinical and Nonclinical Adverse Effects of Kinase Inhibitors
#17 Cardiotoxicity of Kinase inhibitors
#18 Case Studies: Selective Inhibitors of Protein Kinases; Exploiting Demure Features
#19 Torcetrapib and Dalcetrapib Safety: Relevance of Preclinical In-Vitro and In-Vivo Models
#20 Targets associated with drug-related suicidal ideation and behavior

List of Contributors

Daniel J. Antoine

University of Liverpool

Institute of Translational Medicine

Department of Molecular and Clinical Pharmacology

MRC Centre for Drug Safety Science

Liverpool L69 3GE

Richard J. Brennan

Sanofi US

Preclinical Safety

DSAR

153 2nd Ave.

Waltham, MA 02451

USA

Kim L.R. Brouwer

The University of North Carolina at Chapel Hill

UNC Eshelman School of Pharmacy

Division of Pharmacotherapy and Experimental Therapeutics

Chapel Hill, NC 27599

USA

José S. Duca

Novartis Institutes for BioMedical Research

Computer Assisted Drug Discovery

100 Technology Square

Cambridge, MA 02139

USA

Berengere Dumotier

Novartis Institutes for BioMedical Research

Preclinical Safety/Cardiac Electrophysiology

Klybeckstrasse 141, WKL.136.178

4057 Basel

Switzerland

Gül Erdemli

Novartis Institutes for BioMedical Research

Center for Proteomic Chemistry

Ion Channel Group

250 Massachusetts Ave.

Cambridge, MA 02139

USA

Ramy Farid

Schrödinger, Inc.

120 West Forty-Fifth Street, 17th Floor

New York, NY 10036

USA

Alexander Fekete

Novartis Institutes for BioMedical Research

Preclinical Safety

Preclinical Secondary Pharmacology

250 Massachusetts Avenue

Cambridge, MA 02139

USA

Oliver Flint

Bristol-Myers Squibb

Pharmaceutical Candidate

Optimization

Discovery Toxicology

Liberty Drive

Newtown, PA 18940

USA

Gary Gintant

AbbVie

Integrated Science and Technology

Department of Integrative Pharmacology

Abbott Park Road

Abbott Park, IL 60064

USA

Andrea Greiter-Wilke

F. Hoffmann-La Roche Ltd.

Pharmaceuticals/Metabolic DTA

Grenzacherstrasse 124

4070 Basel

Switzerland

Brian Guth

Boehringer Ingelheim Pharma GmbH & Co. KG

General Pharmacology, Drug Discovery Support

Biberach an der Riss

Germany

Robert L. Hamlin

QTest Labs LLC and The Ohio State University

1900 Coffey Road

Columbus, OH 43210

USA

Jacques Hamon

Novartis Institutes for BioMedical Research

Preclinical Safety Profiling

Klybeckstrasse 141

4057 Basel

Switzerland

Andreas Hartmann

Novartis Institutes for BioMedical Research

Preclinical Safety

Klybeckstrasse

4057 Basel

Switzerland

Brett A. Howell

The Hamner Institutes for Health Sciences

The Hamner-UNC Institute for Drug Safety Sciences

Research Triangle Park, NC 27709

USA

Daniel Hoyer

The University of Melbourne

Faculty of Medicine, Dentistry and Health Sciences

School of Medicine

Department of Pharmacology and Therapeutics

Parkville, Victoria 3010

Australia

and

The University of Melbourne

The Florey Institute of Neuroscience and Mental Health

30 Royal Parade

Parkville, Victoria 3052

Australia

and

The Scripps Research Institute

Department of Chemical Physiology

10550 North Torrey Pines Road

La Jolla, CA 92037

USA

Qi-Ying Hu

Novartis Institutes for BioMedical Research

Global Discovery Chemistry

100 Technology Square

Cambridge, MA 02139

USA

Haisong Ju

Novartis Institutes for BioMedical Research Head

Safety Pharmacology-US/Preclinical Safety

Novartis Pharmaceuticals Corporation

One Health Plaza

East Hanover, NJ 07936-1080

USA

Michael J. Keiser

University of California, San Francisco

Department of Pharmaceutical Chemistry

1700 4th Street

San Francisco, CA 94158

USA

and

University of California, San Francisco

Department of Bioengineering and

Therapeutic Sciences

1700 4th Street

San Francisco, CA 94158

USA

and

University of California, San Francisco

Institute for Neurodegenerative Diseases

675 Nelson Rising Lane

San Francisco, CA 94158

USA

Douglas A. Keller

Sanofi US

Preclinical Safety

DSAR

55 Corporate Dr.

Bridgewater, NJ 08807

USA

Gerd A. Kullak-Ublick

University Hospital Zurich

Department of Clinical Pharmacology and Toxicology

Raemistrasse 100

8091 Zurich

Switzerland

Pierre Lainée

Sanofi

DSAR 371, RUE DU PROF JOSEPH BLAYAC

Montpellier 34184

France

Ellen R. Laird

Array BioPharma Inc.

Computational Chemistry

3200 Walnut Street

Boulder, CO 80301

USA

Karen L. Leach

Pfizer

Centers for Therapeutic Innovation

3 Blackfan Circle

Boston, MA 02115

USA

Eugen Lounkine

Novartis Institutes for BioMedical Research

Center for Proteomic Chemistry

In Silico Lead Discovery

250 Massachusetts Avenue

Cambridge, MA 02139

USA

K. Andrew MacCannell

Novartis Institutes for BioMedical Research

100 Technology Square

Cambridge, MA 02139

USA

Mateusz Maciejewski

Novartis Institutes for BioMedical Research

Center for Proteomic Chemistry

Preclinical Safety Profiling

250 Massachusetts Avenue

Cambridge, MA 02139

USA

Frederic Moulin

Bristol-Myers Squibb

Pharmaceutical Candidate Optimization

Discovery Toxicology

Clover Lane

Madison, CT 06443

USA

Lutz Müller

F. Hoffmann-La Roche Ltd.

Pharmaceuticals/Metabolic DTA

Grenzacherstrasse 124

4070 Basel

Switzerland

Patrick Y. Müller

Novartis Pharma

Global Pharma Development Strategy

Fabrikstrasse

4057 Basel

Switzerland

Mark C. Munson

Sanofi US

LGCR-Boston Hub

153 2nd Ave

Waltham, MA, 02451

USA

Eric J. Niesor

F. Hoffmann-La Roche Ltd.

Pharmaceuticals/Metabolic DTA

Grenzacherstrasse 124

4070 Basel

Switzerland

Vinod F. Patel

Sanofi US

LGCR - Boston Hub

153 Second Avenue

Waltham, MA 02451

USA

Robert A. Pearlstein

Novartis Institutes for BioMedical Research

Computer Assisted Drug Discovery

100 Technology Square

Cambridge, MA 02139

USA

Sarita Pereira1)

Novartis Institutes for BioMedical Research

250 Massachusetts Avenue

Cambridge, MA 02139

USA

Dusty Sarazan

Data Sciences International

119 14th Street NW, Suite 100

St. Paul, MN 55112

USA

John R. Senior

Food and Drug Administration

Center for Drug Evaluation and Research

Office of Surveillance and Epidemiology

Office of Pharmacovigilance and Epidemiology

10903 New Hampshire Avenue

Silver Spring, MD 20993-0002

USA

Lisl K. Shoda

The Hamner Institutes for Health Sciences

The Hamner-UNC Institute for Drug Safety Sciences

Research Triangle Park, NC 27709

USA

Scott Q. Siler

The Hamner Institutes for Health Sciences

The Hamner-UNC Institute for Drug Safety Sciences

Research Triangle Park, NC 27709

USA

Matt Skinner

AstraZeneca R&D

Drug Safety and Metabolism

Alderley Park

Macclesfield SK10 4TG

Bruno Stieger

University Hospital Zurich

Department of Clinical Pharmacology and Toxicology

Raemistrasse 100

8091 Zurich

Switzerland

Martin Traebert

Novartis Institutes for BioMedical Research

Preclinical Safety/Cardiac Electrophysiology

Klybeckstrasse 141, WKL.136.178

4057 Basel

Switzerland

Christian Trendelenburg

Novartis Institutes for BioMedical Research

Preclinical Safety

Klybeckstrasse 141,

4057 Basel

Switzerland

László Urbán

Novartis Institutes for BioMedical Research

Preclinical Safety

Preclinical Secondary Pharmacology

250 Massachusetts Avenue

Cambridge, MA 02139

USA

Jean-Pierre Valentin

UCB Biopharma

Investigative Toxicology, Non-Clinical Development

1420 Braine-l'Alleud

Belgium

Roy J. Vaz

Sanofi US

LGCR - Boston Hub

153 Second Avenue

Waltham, MA 02451

USA

Paul B. Watkins

The Hamner Institutes for Health Sciences

The Hamner-UNC Institute for Drug Safety Sciences

Research Triangle Park, NC...

Systemvoraussetzungen

Als PDF speichern Als Link merken